Business Standard

Top headlines: L&T Q3 net falls; nod for Bharat Bio's intranasal dose trial

Business Standard brings you the top headlines on Friday

Bharat Biotech, Covaxin
Premium

Photo: Shutterstock

BS Web Team New Delhi
DCGI gives permission to Bharat Biotech for intranasal booster dose trials

India's drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for its intranasal Covid vaccine as booster dose on participants who have been previously inoculated with SARS-CoV 2 vaccines.

India is yet to approve the use of intranasal COVID-19 vaccine BBV154 developed by the Hyderabad-based company. Read more

India to export BrahMos missiles to Philippines, signs $374-mn deal

India got its first ever export order for BrahMos missiles on Friday when the Philippines' Defence Ministry signed $374 million contract with BrahMos Aerospace Private Limited to supply

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 28 2022 | 5:39 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com